• Edding Genor presented preliminary Phase I results for GB268 in previously treated advanced solid tumors at the ESMO Congress 2026.
• The experimental antibody showed antitumor activity in breast, ovarian and non-small cell lung cancers, including tumors with low PD-L1 expression.
• Treatment was generally well tolerated; one patient experienced dose-limiting lung and heart inflammation that resolved with treatment.
• Dose escalation was completed without reaching the maximum tolerated dose; dose expansion remained ongoing as of September 15, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Edding Genor Group Holdings Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261023-12382250), on October 23, 2026, and is solely responsible for the information contained therein.